Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI7836 Safety and Tolerability in Healthy Adults
NCT02388347Phase 1Completed
- Sponsor
- MedImmune
- Start
- Mar 2015
- Primary completion
- Jan 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MEDI7836 in asthma (5 arms), sponsored by MedImmune. Primary endpoints: Treatment-Emergent Adverse Events, Injection Site Reactions and 3 more. Started Mar 2015; status: completed.
02
Drugs
MEDI7836
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02388347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02388347.